Biliary Tract Cancer, Immune Checkpoint Inhibitor, Predictive Cancer Model
Conditions
Brief summary
1. Establish a predictive model for the efficacy of immune checkpoint inhibitors (ICI) in Chinese patients with biliary tract cancers. By analyzing the dynamic changes of circulating tumor DNA (ctDNA) and other clinical and pathological features before and after ICI treatment in a cohort of patients with biliary tract tumors, a predictive model can be established to evaluate the efficacy of ICI treatment in the early stages or even before treatment, serving as a reliable tool for selecting patients who are likely to benefit from ICI treatment. 2. Investigate the clinical features of populations that benefit from different immune combination therapies. By comparing the differences and enrichment of mutations between patients receiving different treatment regimens, and if patients have sufficient pre-treatment tissue, further comparisons of differentially expressed genes and pathways may be made.
Interventions
DRUGImmune Checkpoint Inhibitors
Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
Sponsors
Geneplus-Beijing Co. Ltd.
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* The subjects voluntarily participate in the study and agree to sign the informed consent form, are compliant, and cooperate with follow-up. * Patients with advanced biliary tract cancers (including gallbladder cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma, or distal cholangiocarcinoma) with histologically, cytologically, or clinically confirmed. * Patients who have undergone curative surgery and experienced disease recurrence after more than 6 months; or patients who have completed adjuvant therapy (chemotherapy and/or radiotherapy) and have been disease-free for more than 6 months after completing adjuvant therapy are eligible for inclusion. * Regardless of gender, age 18-80 years old. * ECOG PS of 0-2 with expected survival time ≥12 weeks. * According to RECIST V1.1, the patient had at least one measurable lesion. * The patient is suitable for treatment with immune checkpoint inhibitors (PD-1/PD-L1 inhibitor).
Exclusion criteria
* Suffering from other malignant tumors. * Previous systemic treatment received. * Patients with serious organic diseases cannot receive the treatment designed in this study; * Having a psychiatric disorder does not guarantee compliance with this study. * Patients with symptomatic brain metastasis or complications related to brain metastasis or cognitive impairment. * Adverse events (except hair loss of any grade) from previous antitumor therapy did not return to ≤ grade 1 or better (According to CTCAE version 5.0). * Previously received any cell or organ transplant treatment. * Allergy to the therapeutic drugs of this study or CT or MRI-enhanced contrast agents. * Received local hepatobiliary treatment (including various types of ablations, percutaneous ethanol or acetic acid injection, high-intensity focused ultrasound, transarterial embolization, chemotherapy, or chemoembolization) within 14 days before the start of the study treatment. * The physician determines that there are any contraindications to ICI treatment. * During the second blood monitoring, the disease changes could not be judged (such as unexplained ascites, worsening symptoms); Or non-disease progression, but the next immunotherapy is not planned.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | Baseline up to approximately 12 months | It refers to the time from the first administration of the regimen to the first occurrence of disease progression or death due to any cause in the subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | Baseline up to approximately 6 months | The proportion of patients whose tumor volume shrinks to a predetermined value and can maintain the minimum required duration, including complete response and partial response. |
| Overall survival | Baseline up to approximately 15 months | The time from randomization to death due to any cause in the subjects. |
| Time to treatment discontinuation | Baseline up to approximately 12 months | The time from the beginning of ICI drug use to the cessation of ICI drug use for any reason |
Countries
China
Outcome results
None listed